title: Recurrent endometrial cancer.
abstract: Endometrial cancer is the most common gynecologic malignancy in the United States. The majority of women are diagnosed with early-stage, low-grade endometrioid tumors that are highly curable with primary surgery. Patients with more advanced and/or higher grade disease require multimodality therapy and have a higher risk for recurrence. Although uterine papillary serous carcinoma and clear cell carcinoma are diagnosed infrequently, they account for almost half of all relapses. As women with recurrent endometrial cancer constitute a heterogeneous group, an individualized approach is required. We review the treatment options of surgery, radiation, hormonal therapy, cytotoxic chemotherapy, and biological agents.
authors.affiliation: Division of Gynecologic Oncology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: Marcela G
authors.initials: MG
authors.lastname: Del Carmen
authors.forename: David M
authors.initials: DM
authors.lastname: Boruta
authors.forename: John O
authors.initials: JO
authors.lastname: Schorge
mesh_terms: D001691:Biological Therapy; D002277:Carcinoma / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010388:Pelvis; D057285:Precision Medicine